{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:28:11Z","timestamp":1786584491297,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75031-7","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:15:34Z","timestamp":1783188934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition"],"prefix":"10.1038","volume":"17","author":[{"given":"Li-Ping","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3684-0816","authenticated-orcid":false,"given":"Yu-Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8060-0995","authenticated-orcid":false,"given":"Song-Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eo-Ryeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-Hong","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-2630","authenticated-orcid":false,"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"75031_CR1","doi-asserted-by":"crossref","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat. Rev. Clinical Oncol. 19, 91\u2013113 (2022).","DOI":"10.1038\/s41571-021-00565-2"},{"key":"75031_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75031_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","volume":"67","author":"M Papadimitriou","year":"2018","unstructured":"Papadimitriou, M., Mountzios, G. & Papadimitriou, C. A. The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality. Cancer Treat. Rev. 67, 34\u201344 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"75031_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"75031_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med"},{"key":"75031_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med 379, 753\u2013763 (2018).","journal-title":"N. Engl. J. Med"},{"key":"75031_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr.","year":"2022","unstructured":"Geyer, C. E. Jr. et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann. Oncol. 33, 1250\u20131268 (2022).","journal-title":"Ann. Oncol."},{"key":"75031_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"75031_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s12276-022-00862-5","volume":"54","author":"S Min","year":"2022","unstructured":"Min, S., Ji, J. H., Heo, Y. & Cho, H. Transcriptional regulation and chromatin dynamics at DNA double-strand breaks. Exp. Mol. Med 54, 1705\u20131712 (2022).","journal-title":"Exp. Mol. Med"},{"key":"75031_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews, H. K., Bertoli, C. & de Bruin, R. A. M. Cell cycle control in cancer. Nat. Rev. Mol. Cell Biol. 23, 74\u201388 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75031_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, M. J. Targeting the DNA damage response in cancer. Mol. Cell 60, 547\u2013560 (2015).","journal-title":"Mol. Cell"},{"key":"75031_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"HHY Chang","year":"2017","unstructured":"Chang, H. H. Y., Pannunzio, N. R., Adachi, N. & Lieber, M. R. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat. Rev. Mol. Cell Biol. 18, 495\u2013506 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75031_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tcb.2018.10.006","volume":"29","author":"A Piazza","year":"2019","unstructured":"Piazza, A. & Heyer, W. D. Homologous recombination and the formation of complex genomic rearrangements. Trends Cell Biol. 29, 135\u2013149 (2019).","journal-title":"Trends Cell Biol."},{"key":"75031_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75031_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2017.71","volume":"3","author":"M Cassandri","year":"2017","unstructured":"Cassandri, M. et al. Zinc-finger proteins in health and disease. Cell Death Discov. 3, 17071 (2017).","journal-title":"Cell Death Discov."},{"key":"75031_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcdb.2020.09.003","volume":"113","author":"JK Singh","year":"2021","unstructured":"Singh, J. K. & van Attikum, H. DNA double-strand break repair: Putting zinc fingers on the sore spot. Semin Cell Dev. Biol. 113, 65\u201374 (2021).","journal-title":"Semin Cell Dev. Biol."},{"key":"75031_CR17","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1038\/sj.onc.1209517","volume":"25","author":"FP Silva","year":"2006","unstructured":"Silva, F. P., Hamamoto, R., Furukawa, Y. & Nakamura, Y. TIPUH1 encodes a novel KRAB zinc-finger protein highly expressed in human hepatocellular carcinomas. Oncogene 25, 5063\u20135070 (2006).","journal-title":"Oncogene"},{"key":"75031_CR18","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.yexcr.2011.05.012","volume":"317","author":"S Shigematsu","year":"2011","unstructured":"Shigematsu, S. et al. ZNF689 suppresses apoptosis of hepatocellular carcinoma cells through the down-regulation of Bcl-2 family members. Exp. Cell Res 317, 1851\u20131859 (2011).","journal-title":"Exp. Cell Res"},{"key":"75031_CR19","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.21037\/tcr-21-994","volume":"10","author":"H Jiang","year":"2021","unstructured":"Jiang, H. et al. MiRNA-339 targets and regulates ZNF689 to inhibit the proliferation and invasion of gastric cancer cells. Transl. Cancer Res. 10, 3516\u20133526 (2021).","journal-title":"Transl. Cancer Res."},{"key":"75031_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41422-023-00909-w","volume":"34","author":"LP Ge","year":"2024","unstructured":"Ge, L. P. et al. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell Res. 34, 58\u201375 (2024).","journal-title":"Cell Res."},{"key":"75031_CR21","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1093\/nar\/gkn550","volume":"36","author":"A Kinner","year":"2008","unstructured":"Kinner, A., Wu, W., Staudt, C. & Iliakis, G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36, 5678\u20135694 (2008).","journal-title":"Nucleic Acids Res."},{"key":"75031_CR22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/nar\/gkx1258","volume":"46","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. ZNF830 mediates cancer chemoresistance through promoting homologous-recombination repair. Nucleic Acids Res. 46, 1266\u20131279 (2018).","journal-title":"Nucleic Acids Res."},{"key":"75031_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01051-z","volume":"8","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. ID3 regulates the MDC1-mediated DNA damage response in order to maintain genome stability. Nat. Commun. 8, 903 (2017).","journal-title":"Nat. Commun."},{"key":"75031_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216308","volume":"570","author":"S Corrales-Guerrero","year":"2023","unstructured":"Corrales-Guerrero, S. et al. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett. 570, 216308 (2023).","journal-title":"Cancer Lett."},{"key":"75031_CR25","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1158\/0008-5472.CAN-09-4224","volume":"70","author":"EV Efimova","year":"2010","unstructured":"Efimova, E. V. et al. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res. 70, 6277\u20136282 (2010).","journal-title":"Cancer Res."},{"key":"75031_CR26","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1080\/15548627.2021.1874209","volume":"17","author":"T Chao","year":"2021","unstructured":"Chao, T. et al. Autophagy restricts mitochondrial DNA damage-induced release of ENDOG (endonuclease G) to regulate genome stability. Autophagy 17, 3444\u20133460 (2021).","journal-title":"Autophagy"},{"key":"75031_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 81\u2013104 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75031_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cell.2018.11.024","volume":"176","author":"RD Jachimowicz","year":"2019","unstructured":"Jachimowicz, R. D. et al. UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell 176, 505\u2013519.e522 (2019).","journal-title":"Cell"},{"key":"75031_CR29","doi-asserted-by":"publisher","first-page":"7720","DOI":"10.1093\/nar\/gku421","volume":"42","author":"MC Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz, M. C., Yanez, D. A. & Stark, J. M. An RNF168 fragment defective for focal accumulation at DNA damage is proficient for inhibition of homologous recombination in BRCA1 deficient cells. Nucleic Acids Res. 42, 7720\u20137733 (2014).","journal-title":"Nucleic Acids Res."},{"key":"75031_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/cr.2008.1","volume":"18","author":"X Li","year":"2008","unstructured":"Li, X. & Heyer, W. D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 18, 99\u2013113 (2008).","journal-title":"Cell Res"},{"key":"75031_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrm3719","volume":"15","author":"S Panier","year":"2014","unstructured":"Panier, S. & Boulton, S. J. Double-strand break repair: 53BP1 comes into focus. Nat. Rev. Mol. Cell Biol. 15, 7\u201318 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75031_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nature03442","volume":"434","author":"J Falck","year":"2005","unstructured":"Falck, J., Coates, J. & Jackson, S. P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434, 605\u2013611 (2005).","journal-title":"Nature"},{"key":"75031_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09641-9","volume":"10","author":"GH Ha","year":"2019","unstructured":"Ha, G. H. et al. Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks. Nat. Commun. 10, 1577 (2019).","journal-title":"Nat. Commun."},{"key":"75031_CR34","doi-asserted-by":"publisher","first-page":"43984","DOI":"10.1074\/jbc.M112.421545","volume":"287","author":"CS Lu","year":"2012","unstructured":"Lu, C. S. et al. The RING finger protein RNF8 ubiquitinates Nbs1 to promote DNA double-strand break repair by homologous recombination. J. Biol. Chem. 287, 43984\u201343994 (2012).","journal-title":"J. Biol. Chem."},{"key":"75031_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.molcel.2012.02.018","volume":"46","author":"J Wu","year":"2012","unstructured":"Wu, J. et al. Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol. Cell 46, 351\u2013361 (2012).","journal-title":"Mol. Cell"},{"key":"75031_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nature07959","volume":"458","author":"VG Bhoj","year":"2009","unstructured":"Bhoj, V. G. & Chen, Z. J. Ubiquitylation in innate and adaptive immunity. Nature 458, 430\u2013437 (2009).","journal-title":"Nature"},{"key":"75031_CR37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1126\/science.1175065","volume":"325","author":"WL Yang","year":"2009","unstructured":"Yang, W. L. et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134\u20131138 (2009).","journal-title":"Science"},{"key":"75031_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386.e310 (2018).","journal-title":"Cell"},{"key":"75031_CR39","doi-asserted-by":"crossref","unstructured":"Yang, L. et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci. Transl. Med. 9, eaal1645 (2017)","DOI":"10.1126\/scitranslmed.aal1645"},{"key":"75031_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl, S. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 19, 497\u2013509 (2018).","journal-title":"Lancet Oncol."},{"key":"75031_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","volume":"24","author":"E Rodler","year":"2023","unstructured":"Rodler, E. et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 24, 162\u2013174 (2023).","journal-title":"Lancet Oncol."},{"key":"75031_CR42","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli, M. L. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22, 3764\u20133773 (2016).","journal-title":"Clin. Cancer Res."},{"key":"75031_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16142-7","volume":"11","author":"N Chopra","year":"2020","unstructured":"Chopra, N. et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat. Commun. 11, 2662 (2020).","journal-title":"Nat. Commun."},{"key":"75031_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf, D. M. et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell 40, 609\u2013623.e606 (2022).","journal-title":"Cancer Cell"},{"key":"75031_CR45","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"75031_CR46","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"KP Hopfner","year":"2020","unstructured":"Hopfner, K. P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501\u2013521 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75031_CR47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"75031_CR48","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med 27, 1250\u20131261 (2021).","journal-title":"Nat. Med"},{"key":"75031_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/35044000","volume":"408","author":"R Scully","year":"2000","unstructured":"Scully, R. & Livingston, D. M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408, 429\u2013432 (2000).","journal-title":"Nature"},{"key":"75031_CR50","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung, N. et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J. Clin. Oncol. 34, 1460\u20131468 (2016).","journal-title":"J. Clin. Oncol."},{"key":"75031_CR51","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1101\/gad.349431.122","volume":"36","author":"JL Hopkins","year":"2022","unstructured":"Hopkins, J. L., Lan, L. & Zou, L. DNA repair defects in cancer and therapeutic opportunities. Genes Dev. 36, 278\u2013293 (2022).","journal-title":"Genes Dev."},{"key":"75031_CR52","first-page":"5122","volume":"16","author":"PS Yi","year":"2018","unstructured":"Yi, P. S., Wu, B., Deng, D. W., Zhang, G. N. & Li, J. S. Positive expression of ZNF689 indicates poor prognosis of hepatocellular carcinoma. Oncol. Lett. 16, 5122\u20135130 (2018).","journal-title":"Oncol. Lett."},{"key":"75031_CR53","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/DDDT.S186352","volume":"13","author":"H Zeng","year":"2019","unstructured":"Zeng, H. et al. MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689. Drug Des. Dev. Ther. 13, 435\u2013445 (2019).","journal-title":"Drug Des. Dev. Ther."},{"key":"75031_CR54","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.12659\/MSM.917038","volume":"25","author":"Z Yu","year":"2019","unstructured":"Yu, Z., Zhao, S., Wang, L., Wang, J. & Zhou, J. miRNA-339-5p plays an important role in invasion and migration of pancreatic cancer cells. Med. Sci. Monit. 25, 7509\u20137517 (2019).","journal-title":"Med. Sci. Monit."},{"key":"75031_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.07.002","volume":"203","author":"MH Jin","year":"2019","unstructured":"Jin, M. H. & Oh, D. Y. ATM in DNA repair in cancer. Pharm. Ther. 203, 107391 (2019).","journal-title":"Pharm. Ther."},{"key":"75031_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cr.7310007","volume":"16","author":"Y Zhang","year":"2006","unstructured":"Zhang, Y., Zhou, J. & Lim, C. U. The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control. Cell Res. 16, 45\u201354 (2006).","journal-title":"Cell Res."},{"key":"75031_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-biochem-062917-012415","volume":"87","author":"A Syed","year":"2018","unstructured":"Syed, A. & Tainer, J. A. The MRE11-RAD50-NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair. Annu. Rev. Biochem. 87, 263\u2013294 (2018).","journal-title":"Annu. Rev. Biochem."},{"key":"75031_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1100-5","volume":"18","author":"L Bian","year":"2019","unstructured":"Bian, L., Meng, Y., Zhang, M. & Li, D. MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. Mol. Cancer 18, 169 (2019).","journal-title":"Mol. Cancer"},{"key":"75031_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-genet-071719-020312","volume":"55","author":"P Cejka","year":"2021","unstructured":"Cejka, P. & Symington, L. S. DNA end resection: mechanism and control. Annu. Rev. Genet. 55, 285\u2013307 (2021).","journal-title":"Annu. Rev. Genet."},{"key":"75031_CR60","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrm.2017.56","volume":"18","author":"J Stingele","year":"2017","unstructured":"Stingele, J., Bellelli, R. & Boulton, S. J. Mechanisms of DNA-protein crosslink repair. Nat. Rev. Mol. Cell Biol. 18, 563\u2013573 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75031_CR61","doi-asserted-by":"crossref","unstructured":"Gupta, S. K. et al. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J. Natl. Cancer Inst. 108, djv369 (2016)","DOI":"10.1093\/jnci\/djv369"},{"key":"75031_CR62","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras, V. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 1269\u20131282 (2020).","journal-title":"Lancet Oncol."},{"key":"75031_CR63","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cllc.2022.01.005","volume":"23","author":"R Govindan","year":"2022","unstructured":"Govindan, R. et al. Veliparib plus carboplatin and paclitaxel versus investigator\u2019s choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer. Clin. Lung Cancer 23, 214\u2013225 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"75031_CR64","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"75031_CR65","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.trecan.2021.08.007","volume":"7","author":"K Fugger","year":"2021","unstructured":"Fugger, K., Hewitt, G., West, S. C. & Boulton, S. J. Tackling PARP inhibitor resistance. Trends Cancer 7, 1102\u20131118 (2021).","journal-title":"Trends Cancer"},{"key":"75031_CR66","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti, S. et al. PARP inhibitors for breast cancer treatment: a review. JAMA Oncol. 10, 658\u2013670 (2024).","journal-title":"JAMA Oncol."},{"key":"75031_CR67","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972\u20132980.e2975 (2018).","journal-title":"Cell Rep."},{"key":"75031_CR68","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak, S. et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5, 1132\u20131140 (2019).","journal-title":"JAMA Oncol."},{"key":"75031_CR69","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek, S. M. et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 21, 1155\u20131164 (2020).","journal-title":"Lancet Oncol."},{"key":"75031_CR70","doi-asserted-by":"publisher","first-page":"CT145","DOI":"10.1158\/1538-7445.AM2023-CT145","volume":"83","author":"KA Fanucci","year":"2023","unstructured":"Fanucci, K. A. et al. Abstract CT145: Olaparib +\/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial. Cancer Res. 83, CT145\u2013CT145 (2023).","journal-title":"Cancer Res."},{"key":"75031_CR71","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss, K. A. et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 23, 1009\u20131020 (2022).","journal-title":"Lancet Oncol."},{"key":"75031_CR72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin, S. N. et al. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J. Clin. Oncol. 42, 283\u2013299 (2024).","journal-title":"J. Clin. Oncol."},{"key":"75031_CR73","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/978-1-61779-998-3_27","volume":"920","author":"A Gunn","year":"2012","unstructured":"Gunn, A. & Stark, J. M. I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. Methods Mol. Biol. 920, 379\u2013391 (2012).","journal-title":"Methods Mol. Biol."},{"key":"75031_CR74","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/nprot.2006.468","volume":"1","author":"A Shevchenko","year":"2006","unstructured":"Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V. & Mann, M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat. Protoc. 1, 2856\u20132860 (2006).","journal-title":"Nat. Protoc."},{"key":"75031_CR75","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"75031_CR76","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"75031_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. npj Breast Cancer 4, 16 (2018).","journal-title":"npj Breast Cancer"},{"key":"75031_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms, K. M. et al. Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16, 475 (2014).","journal-title":"Breast Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75031-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:01:36Z","timestamp":1786582896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75031-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75031"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75031-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8329"}}